Trial Profile
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Etanercept (Primary) ; Methylprednisolone
- Indications Pneumonia
- Focus Therapeutic Use
- 07 Feb 2017 Status changed from active, no longer recruiting to completed.
- 19 Oct 2015 New trial record